Lin Ma

Dr. Lin Ma

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2024 in Neuroscience
Verified
Journal Article
Closed access
JCJuan Chen
Juan Chen
YGYuan Gao
Yuan Gao
NLNing Liu
Ning Liu
DHDongmei Hai
Dongmei Hai
WWWei Wei
Wei Wei
LMLin Ma
Lin Ma

12 June 2023 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
YGYuan Gao
Yuan Gao
NLNing Liu
Ning Liu
JCJuan Chen
Juan Chen
PZPing Zheng
Ping Zheng
JNJianguo Niu
Jianguo Niu
LMLin Ma
Lin Ma
Background: Posttraumatic epilepsy (PTE) is one of the most critical complications of traumatic brain injury (TBI), significantly increasing TBI patients' neuropsychiatric symptoms and mortality. The abnormal accumulation of glutamate caused by TBI and its secondary excitotoxicity are essential reasons for neural network reorganization and functional neural plasticity changes, contributing to the occurrence and development of PTE. Restoring glutamate balance in the early stage of TBI is expected to play a neuroprotective role and reduce the risk of PTE.Aims: To provide a neuropharmacological insight for drug development to prevent PTE based on regulating glutamate homeostasis.Methods: We discussed how TBI affects glutamate homeostasis and its relationship with PTE. Furthermore, we also summarized the research progress of molecular pathways for regulating glutamate homeostasis after TBI and pharmacological studies aim to prevent PTE by restoring glutamate balance.Results: TBI can lead to the accumulation of glutamate in the brain, which increases the risk of PTE. Targeting the molecular pathways affecting glutamate homeostasis helps restore normal glutamate levels and is neuroprotective.Discussion: Taking glutamate homeostasis regulation as a means for new drug development can avoid the side effects caused by direct inhibition of glutamate receptors, expecting to alleviate the diseases related to abnormal glutamate levels in the brain, such as PTE, Parkinson's disease, depression, and cognitive impairment.Conclusion: It is a promising strategy to regulate glutamate homeostasis through pharmacological methods after TBI, thereby decreasing nerve injury and preventing PTE.

22 October 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MTMiao-Miao Tian
Miao-Miao Tian
GLGang Liu
Gang Liu
JDJuan Du
Juan Du
YLYue Liu
Yue Liu
Wei WeiWei Wei
Wei Wei
NLNing Liu
Ning Liu
Background: Epilepsy is a prevalent and disabling neurological condition characterized by recurrent seizures. Approximately 50% of adults with active epilepsy have at least one comorbidity and they are at a greater risk of premature death than the general population. Gentiopicroside (Gent) is a primary component of Gentiana macrophylla Pall. that has been shown to have diverse pharmacological properties. However, its role in epileptic seizures in adult mice and its underlying mechanism of action remain obscure. We aimed to explore the anti-epileptic effect and mechanism of Gent on lithium/pilocarpine (Pilo)-induced epilepsy seizures in mice. Methods: In this study, we established a lithium/Pilo-induced epilepsy model, and Gent was first given to mice 30 min before Pilo administration. Then, we detected behavioral and histopathological changes through electrocorticographic (ECoG) measurements, Nissl staining, Fluoro-Jade B (FJB) staining, and immunohistochemical staining. We then used molecular biology techniques, such as Western blotting, quantitative polymerase chain reaction (qPCR) analysis, and the enzyme-linked immunosorbent assay (ELISA) to investigate the mechanisms of Gent in lithium/Pilo-induced epileptic seizures in mice and lipopolysaccharide (LPS)-induced inflammatory astrocytes. Results: We confirmed that Gent could prevent abnormal ECoG activity, behavioral changes, and neurodegeneration. Subsequently, we found Gent could downregulate the factors that could promote apoptosis (i.e., the NR2B/CaMKII/CREB signaling cascade) and neuroinflammatory-related factors (i.e., the TLR4/NF-κB signaling cascade). Conclusions: Gent could be a potential therapeutic agent for epilepsy, offering possibilities for both prevention and treatment. Our research establishes a preliminary experimental framework for ongoing studies into Gent’s efficacy as a treatment for epilepsy.

29 May 2025 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
LMLin Ma
Lin Ma
YGYuan Gao
Yuan Gao
JCJuan Chen
Juan Chen
DHDongmei Hai
Dongmei Hai
JYJianqiang Yu
Jianqiang Yu
YLYue Liu
Yue Liu

1 November 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
ZCZhen-Hong Cheng
Zhen-Hong Cheng
NLNing Liu
Ning Liu
YLYue Liu
Yue Liu
LMLin Ma
Lin Ma
XLXiao-Bing Lan
Xiao-Bing Lan
Wei WeiWei Wei
Wei Wei
Cistanche deserticola is a perennial parasitic herb of the Orobanchaceae family and a traditional Chinese medicinal material included in the homology-of-medicine-and-food category. It has traditionally been used to nourish the kidney and essence and to relieve constipation. Recent studies have investigated its potential effects on intestinal motility, gut microbiota, and fecal water regulation. This review summarizes the reported chemical constituents of C. deserticola, including phenylethanoid glycosides, polysaccharides, flavonoids, and sugar alcohols, and examines the available evidence regarding their potential contributions to laxative effects. Possible mechanisms involving intestinal motility, neurotransmitter-related signaling, gut microbiota and microbial metabolites, and aquaporin expression are discussed. Evidence is considered hierarchically: findings from identified C. deserticola preparations are distinguished from indirect findings involving other Cistanche species, isolated compounds, or multi-component herbal formulations, while proposed causal pathways are treated as hypotheses unless directly tested. The evidence base is predominantly preclinical, and human studies are limited; the specific contributions of individual constituents, the causal relationships underlying the proposed mechanisms, and the long-term safety of different preparations remain insufficiently established. This review also discusses challenges in raw-material standardization, evidence-based quality control, and functional food development, highlighting the need for further mechanistic, toxicological, and clinical studies to support the rational development of C. deserticola-based products.